JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol , total cholesterol , apolipoprotein B , and non-high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia . Limitations of Use The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia . The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined .